Anfield Capital Management LLC Has $2.58 Million Holdings in Roivant Sciences Ltd. $ROIV

Key Points

• Anfield Capital Management trimmed its Roivant stake by 23.6% to 118,951 shares worth $2.58 million, leaving ROIV as about 0.8% of the firm's portfolio and its 26th-largest holding.
• Significant insider selling occurred recently—insiders sold 5,085,398 shares totaling about $139.2 million over the last three months (including sales by Mayukh Sukhatme and CEO Eric Venker), with insiders now owning 10.8% of the stock.
• Analysts maintain a consensus "Moderate Buy" (10 Buys, 1 Hold, 1 Sell) with an average price target of $30.55; ROIV trades near its 50-day SMA (~$28) and has a 52-week range of $10.58–$30.33.

Anfield Capital Management LLC cut its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 23.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 118,951 shares of the company's stock after selling 36,693 shares during the period. Roivant Sciences accounts for about 0.8% of Anfield Capital Management LLC's investment portfolio, making the stock its 26th biggest position. Anfield Capital Management LLC's holdings in Roivant Sciences were worth $2,581,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ROIV. Jones Financial Companies Lllp boosted its position in Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company's stock valued at $25,000 after buying an additional 1,148 shares in the last quarter. SBI Securities Co. Ltd. boosted its position in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock valued at $27,000 after buying an additional 1,166 shares in the last quarter. Allworth Financial LP lifted its position in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after purchasing an additional 583 shares in the last quarter. Bessemer Group Inc. lifted its position in shares of Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock worth $28,000 after purchasing an additional 543 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its position in shares of Roivant Sciences by 204.2% during the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company's stock worth $65,000 after purchasing an additional 3,882 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $28.28 on Friday. The company's 50 day simple moving average is $28.34 and its 200 day simple moving average is $24.25. Roivant Sciences Ltd. has a fifty-two week low of $10.58 and a fifty-two week high of $30.33. The firm has a market capitalization of $20.24 billion, a P/E ratio of -24.17 and a beta of 1.14.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Guggenheim upped their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Weiss Ratings lowered shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a research report on Monday, February 9th. Piper Sandler upped their target price on shares of Roivant Sciences from $22.00 to $40.00 and gave the stock an "overweight" rating in a research report on Thursday, April 16th. Sanford C. Bernstein assumed coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They set an "outperform" rating and a $35.00 target price on the stock. Finally, Jefferies Financial Group reiterated a "buy" rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $30.55.

Insiders Place Their Bets

In other Roivant Sciences news, insider Mayukh Sukhatme sold 339,441 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $26.47, for a total value of $8,985,003.27. Following the sale, the insider directly owned 19,148,664 shares in the company, valued at approximately $506,865,136.08. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.49, for a total transaction of $5,298,000.00. Following the completion of the sale, the chief executive officer owned 1,654,597 shares in the company, valued at approximately $43,830,274.53. This trade represents a 10.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,085,398 shares of company stock valued at $139,215,946 over the last three months. 10.80% of the stock is owned by insiders.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.